Arnie P Aldridge1, Gary A Zarkin1, William N Dowd1, Jeremy W Bray2. 1. Behavioral Health Economics Program , RTI International, Research Triangle Park, North Carolina. 2. Bryan School of Business and Economics , University of North Carolina, Greensboro, North Carolina.
Abstract
BACKGROUND: A challenge for evaluating alcohol treatment efficacy is determining what constitutes a "good" outcome or meaningful improvement. Abstinence at the end of treatment is an unambiguously good outcome; however, a focus on abstinence ignores the potential benefits of patients reducing their drinking to less problematic levels. Patients may be drinking at low-risk levels at the end of treatment but may be high-functioning and impose few social costs. In this study, we estimate the relationship between drinking at the end of COMBINE treatment and subsequent healthcare costs with an emphasis on heavy and nonheavy drinking levels. METHODS: Indicators of heavy drinking days (HDDs; 5+ drinks for men, 4+ for women) and nonheavy drinking days (non-HDDs) during the last 30 days of COMBINE treatment were constructed for 748 patients enrolled in the COMBINE Economic Study. Generalized linear models were used to model total costs following COMBINE treatment as a function of drinking indicators. Different model specifications analyzed alternative counts of HDDs (e.g., 1 HDD and 2 to 30 HDDs), and groups having Both non-HDDs and HDDs. RESULTS: Patients with HDDs had 66.4% (p < 0.01) higher healthcare costs than those who were abstinent. Having more than 2 HDDs was associated with the highest costs (75.9%, p < 0.01). Patients with non-HDDs had costs that were not significantly different than abstainers, even if they also had HDDs. However, those with HDDs only had costs 91.7% higher than abstainers (p < 0.01). CONCLUSIONS: Having HDDs at the end of treatment is associated with higher costs. Patients who had Only HDDs at the end of treatment had worse subsequent outcomes than those who had Both non-HDDs and HDDs. These findings offer new context for evaluating treatment outcomes and provide new information on the association of drinking with consequences.
BACKGROUND: A challenge for evaluating alcohol treatment efficacy is determining what constitutes a "good" outcome or meaningful improvement. Abstinence at the end of treatment is an unambiguously good outcome; however, a focus on abstinence ignores the potential benefits of patients reducing their drinking to less problematic levels. Patients may be drinking at low-risk levels at the end of treatment but may be high-functioning and impose few social costs. In this study, we estimate the relationship between drinking at the end of COMBINE treatment and subsequent healthcare costs with an emphasis on heavy and nonheavy drinking levels. METHODS: Indicators of heavy drinking days (HDDs; 5+ drinks for men, 4+ for women) and nonheavy drinking days (non-HDDs) during the last 30 days of COMBINE treatment were constructed for 748 patients enrolled in the COMBINE Economic Study. Generalized linear models were used to model total costs following COMBINE treatment as a function of drinking indicators. Different model specifications analyzed alternative counts of HDDs (e.g., 1 HDD and 2 to 30 HDDs), and groups having Both non-HDDs and HDDs. RESULTS: Patients with HDDs had 66.4% (p < 0.01) higher healthcare costs than those who were abstinent. Having more than 2 HDDs was associated with the highest costs (75.9%, p < 0.01). Patients with non-HDDs had costs that were not significantly different than abstainers, even if they also had HDDs. However, those with HDDs only had costs 91.7% higher than abstainers (p < 0.01). CONCLUSIONS: Having HDDs at the end of treatment is associated with higher costs. Patients who had Only HDDs at the end of treatment had worse subsequent outcomes than those who had Both non-HDDs and HDDs. These findings offer new context for evaluating treatment outcomes and provide new information on the association of drinking with consequences.
Authors: Andrea H Kline-Simon; Constance M Weisner; Sujaya Parthasarathy; Daniel E Falk; Raye Z Litten; Jennifer R Mertens Journal: Alcohol Clin Exp Res Date: 2013-10-07 Impact factor: 3.455
Authors: Gary A Zarkin; Jeremy W Bray; Arnie Aldridge; Michael Mills; Ron A Cisler; David Couper; James R McKay; Stephanie O'Malley Journal: Med Care Date: 2010-05 Impact factor: 2.983
Authors: Jeremy W Bray; Gary A Zarkin; William R Miller; Debanjali Mitra; Daniel R Kivlahan; Daniel J Martin; David J Couper; Ron A Cisler Journal: J Stud Alcohol Drugs Date: 2007-03 Impact factor: 2.582
Authors: Katie Witkiewitz; Henry R Kranzler; Kevin A Hallgren; Stephanie S O'Malley; Daniel E Falk; Raye Z Litten; Deborah S Hasin; Karl F Mann; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2018-11-05 Impact factor: 3.455
Authors: Brian D Kiluk; Tami L Frankforter; Michelle Cusumano; Charla Nich; Kathleen M Carroll Journal: Alcohol Clin Exp Res Date: 2018-06-05 Impact factor: 3.455
Authors: Stephen A Maisto; Corey R Roos; Kevin A Hallgren; Dezarie Moskal; Adam D Wilson; Katie Witkiewitz Journal: Alcohol Clin Exp Res Date: 2016-09-03 Impact factor: 3.455
Authors: Arnie P Aldridge; Gary A Zarkin; William N Dowd; Katie Witkiewitz; Deborah S Hasin; Stephanie S O'Malley; Keith Isenberg; Raymond F Anton Journal: J Addict Med Date: 2021-12-03 Impact factor: 4.647
Authors: Katie Witkiewitz; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Corey R Roos; Megan Kirouac; Adam D Wilson; Kevin S Montes; Nick Heather Journal: Addiction Date: 2017-06-26 Impact factor: 6.526
Authors: Katie Witkiewitz; Corey R Roos; Matthew R Pearson; Kevin A Hallgren; Stephen A Maisto; Megan Kirouac; Alyssa A Forcehimes; Adam D Wilson; Charles S Robinson; Elizabeth McCallion; J Scott Tonigan; Nick Heather Journal: J Stud Alcohol Drugs Date: 2017-01 Impact factor: 2.582
Authors: Daniel E Falk; Stephanie S O'Malley; Katie Witkiewitz; Raymond F Anton; Raye Z Litten; Megan Slater; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Bankole Johnson; Didier Meulien; Megan Ryan; Joanne Fertig Journal: JAMA Psychiatry Date: 2019-04-01 Impact factor: 25.911
Authors: Katie Witkiewitz; Kevin A Hallgren; Henry R Kranzler; Karl F Mann; Deborah S Hasin; Daniel E Falk; Raye Z Litten; Stephanie S O'Malley; Raymond F Anton Journal: Alcohol Clin Exp Res Date: 2016-12-26 Impact factor: 3.455